Summary of the Medical Aesthetic Industry Conference Call Industry Overview - The medical aesthetic industry is experiencing intensified competition, with upstream companies facing profit erosion on single products and downstream chain medical aesthetic institutions accelerating mergers and acquisitions. Leading brands like Meili Tianyuan are emerging, indicating a shift from product-driven growth to user demand-driven growth, resulting in a transfer of power within the industry towards downstream players [1][2][16]. Key Points on Companies Juzhi Biotechnology - In the first half of 2025, Juzhi Biotechnology's sales were impacted by a public relations incident, with its brand Kefu Mei not recovering sales during the Double Eleven shopping festival. Contributing factors include underwhelming influencer marketing recovery and a 20% reduction in advertising budget. The GMV from Douyin channel dropped over 60% year-on-year, reflecting challenges in brand marketing strategies [1][4][3]. Jinbo Biotechnology - Jinbo Biotechnology's revenue and profit growth slowed in Q3 2025, primarily due to price erosion of its core product, the 4mg ultra-pure product, which saw its terminal price drop from a suggested retail price of 6,800 yuan to just over 1,000 yuan. The company is expanding its distribution channels to 4,000, which is lower than competitors like facial fillers. New product launches are facing high sales expense ratios, putting pressure on profits [1][5][8]. Meili Tianyuan - Meili Tianyuan has distinguished itself through excellent user operations, digital membership management, and effective acquisition strategies. The brand has maintained same-store growth of 5% to 6% over the past two years, with a 10% increase in user numbers offsetting a 5% decline in average transaction value. The company has expanded its scale through acquisitions, increasing its store count to around 700-800 [1][11][10]. Industry Dynamics - Downstream chain medical aesthetic institutions are enhancing their operational capabilities through mergers and acquisitions, which is increasing their bargaining power. Leading brands like Meili Tianyuan are establishing close ties with upstream companies through customized collaborations, achieving mutual growth [1][6][12]. Challenges and Opportunities - Upstream companies are facing increased competition and declining profits on single products, necessitating strategic adjustments to attract users. Downstream institutions are experiencing high customer acquisition costs and insufficient standardization of products, leading to increased survival pressure. However, those companies that can effectively manage user needs and supply chain advantages are likely to emerge successfully from the current challenges [1][9][16]. Conclusion - The medical aesthetic industry is transitioning from a phase of rapid growth to one characterized by demand stabilization and intensified competition. Downstream companies must adapt quickly to market changes, while upstream companies need to enhance their channel management capabilities. Despite the challenges, companies that excel in user demand understanding and membership operations are positioned to achieve new growth [1][16][15].

Summary of the Conference Call for Xinyang Company Overview - Xinyang operates in the medical aesthetics industry, primarily through an online platform that charges information service fees and commissions to medical beauty institutions. The company was founded in 2013 and went public on NASDAQ in 2019. [3][2] Key Business Developments - Xinyang acquired Wuhan Qizhi Laser for 790 million RMB to expand its photonic equipment business and is also the agent for Dongbang's hyaluronic acid products from South Korea, with a quarterly shipment of 28,000 units, a 14% year-on-year increase. [2][3] - The core business, Xinyang Youth Clinics, has opened 31 locations and plans to expand to 50 by 2025, focusing on first-tier cities. [2][5] Financial Performance - Expected revenue for 2025 is between 1.5 billion to 1.6 billion RMB, with contributions from various segments: Top business (500-600 million RMB), chain business (600 million RMB), and upstream business (300 million RMB). [3][12] - The average monthly revenue for mature clinics is 4.5 to 5 million RMB, while growing clinics average around 3 million RMB. [6][7] Customer Insights - Target customers are women aged 25-45, with the highest spending power in the 30-35 age range. The repurchase rate is approximately 60-65%. [9][10] - Average customer spending is 2,000 RMB for new customers and 2,500 RMB for returning customers. [8] Marketing and Customer Acquisition - Xinyang's customer acquisition cost is significantly lower than industry averages, with costs around 700 RMB per customer compared to 2,000-3,000 RMB for competitors. [10][22] - The company utilizes a mix of referral programs, private domain conversions, and social media advertising to attract new customers. [10][11] Operational Efficiency - The cost structure includes marketing expenses (15%), consumable costs (49-50%), personnel costs (12%), and rent/utilities (10-15%). [6][20] - The company has a strong focus on light medical aesthetics, which facilitates replication and expansion. [8] Product Development and Innovation - Xinyang plans to launch proprietary products such as the "童颜针" (youthful needle) and silk protein to enhance cost-effectiveness and competitiveness. [3][13] - New products are designed to improve user experience and reduce costs, with a focus on maintaining a competitive edge in pricing and efficacy. [14][22] Store Expansion Strategy - The company plans to open 50 stores by the end of 2025, with a mix of direct and franchise operations. [17][18] - The payback period for stores is estimated at around six months for positive cash flow and one year for breakeven. [19] Competitive Landscape - Xinyang's business model is unique in the market, with few direct competitors. Similar models exist, but they differ significantly in scale and operations. [28] Conclusion - Xinyang is positioned for growth in the medical aesthetics sector, with a solid expansion plan, innovative product offerings, and a strong customer acquisition strategy. The company aims to leverage its unique business model to maintain a competitive advantage in the industry. [2][3][28]